Search Results
Jun 25, 2026, 08:00 ET MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California Facility
the world.BIOLASE®, Waterlase® and Waterlase iPlus®, and Epic® are registered trademarks of BIOLASE MG LLC.For updates and information on BIOLASE and laser dentistry, find BIOLASE online at
More news about: BIOLASE
Jun 25, 2026, 07:00 ET Terrabis Illinois Dispensaries Launch Recreational Curbside Pickup Following SB 3222
shoppers.Illinois residents may now purchase and possess up to 60 grams of flower, 1,000 mg of infused products, and 10 grams of concentrate. Out-of-state visitors may now purchase and possess up to 30 grams of flower, 500 mg of infused products, and 5 grams of concentrate.The new cannabis laws in Illinois
More news about: Terrabis
Jun 25, 2026, 06:45 ET What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5.5 mg (via steps at 0.8 mg and 2.5 mg), 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). These
More news about: Eli Lilly and Company
Jun 25, 2026, 05:55 ET New report: CivicaScript saved patients & payers more than $16 million in generic medicine costs in 2025
reflects the savings from CivicaScript products as of their first full quarter of availability.1 Ustekinumab-aauz injection, 45 mg/0.5mL and 90 mg/mL2 Stelara® is a registered trademark of Johnson & Johnson.3 CalRx® is a registered
More news about: Civica Rx
Jun 24, 2026, 16:15 ET CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes
patients continue to require high insulin doses and fail to consistently achieve target glucose ranges. For this study, glucose time-in-range (70-180 mg/dL) via continuous glucose monitoring is the primary endpoint. Key secondary and exploratory endpoints include HbA1c, total daily insulin dose, insulin
More news about: Cirius Therapeutics
Jun 24, 2026, 09:00 ET Knoa Pharma and GCAR Announce First Newly Diagnosed Glioblastoma Patient Randomized in Phase 2/3 GBM AGILE Evaluation of Tinostamustine and First Recurrent Patient Dosed
glioblastoma."In an earlier Phase 1 trial of tinostamustine in patients with uMGMT GBM, results showed tinostamustine to be tolerable at doses of 80 to 100 mg/m², with manageable side effects. While the Phase 1 study was not designed to demonstrate efficacy, exploratory analyses of progression-free and overall
More news about: Knoa Pharma
Jun 24, 2026, 07:13 ET RelaxPLX® Gains Health Canada License, and South Korean Sleep Quality Support Claim
was a demanding, multi-stage project from dossier preparation through to final recognition. The objective was to demonstrate that a daily intake of 400mg/day of RelaxPLX's® lemon verbena (Aloysia citrodora) extract may help to improve sleep quality.To obtain this status, an ingredient
More news about: Monteloeder, S.L.
Jun 24, 2026, 03:49 ET Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
(eptinezumab)Eptinezumab is a humanized mAb that binds to CGRP which was developed for intravenous (IV) administration. The efficacy and safety of eptinezumab 100 mg and 300 mg was investigated in two Phase III clinical trials (PROMISE-1 in episodic migraine[5] and PROMISE-2 in chronic migraine).[6]
More news about: H. Lundbeck A/S
Jun 24, 2026, 03:01 ET Avinox Unveils the Avinox MG Concept Product at Eurobike 2026
bringing them the best cycling experience imaginable."The Avinox MG Concept Motor RevealedThe MG Concept is Avinox's first concept product, created in partnership with Canyon, Commencal, Forbidden, and Mondraker. The MG Concept motor will be presented for the first time publically at Avinox's
More news about: Avinox
Jun 24, 2026, 03:01 ET Avinox Unveils the Avinox MG Concept Product at Eurobike 2026
bringing them the best cycling experience imaginable."The Avinox MG Concept Motor RevealedThe MG Concept is Avinox's first concept product, created in partnership with Canyon, Commencal, Forbidden, and Mondraker. The MG Concept motor will be presented for the first time publically at Avinox's
More news about: Avinox
Jun 24, 2026, 03:01 ET Avinox presenta il prodotto concept Avinox MG1 a Eurobike 2026
ciclistica immaginabile".Svelato il motore Avinox MG Conceptil motore Avinox MG Concept è il primo prodotto concept di Avinox, creato in collaborazione con Canyon, Commencal, Forbidden, e Mondraker. il motore Avinox MG Concept sarà presentato per la prima volta al pubblico presso
More news about: Avinox
Jun 24, 2026, 03:01 ET Avinox dévoile le concept produit Avinox MG1 à l'Eurobike 2026
meilleure expérience de cycliste imaginable. »Le moteur Avinox MG Concept dévoiléLe MG est le premier produit conceptuel d'Avinox, créé en partenariat avec Canyon, Commencal, Forbidden, and Mondraker. Le MG sera présenté pour la première fois au public sur le stand Avinox à l'Eurobike.Les
More news about: Avinox
Jun 24, 2026, 03:01 ET Avinox presenta el producto conceptual Avinox MG1 en Eurobike 2026
experiencia ciclista imaginable".Avinox presenta el motor MG ConceptEl motor MG Concept es el primer producto conceptual de Avinox, creado conjuntamente con Canyon, Commencal, Forbidden, y Mondraker. El motor MG Concept se presentará al público por primera vez en el stand de Avinox
More news about: Avinox
Jun 24, 2026, 03:01 ET Avinox stellt auf der Eurobike 2026 den Avinox MG Concept Motor vor
Fahrerlebnis zu bieten."Vorstellung des Avinox MG Concept MotorsDer MG Concept ist das erste Konzeptprodukt von Avinox und wurde in Zusammenarbeit mit Canyon, Commencal, Forbidden, Mondraker und Megamo entwickelt. Der MG Concept Motor wird erstmals am Avinox-Stand auf der Eurobike
More news about: Avinox
Jun 23, 2026, 12:15 ET INVESTOR ALERT: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jun 23, 2026, 10:00 ET UPSHER-SMITH EXPANDS KYMBEE™ (DEFLAZACORT) FAMILY OF PRODUCTS WITH LAUNCH OF ORAL SUSPENSION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. KYMBEE is available in 6 mg, 18 mg, 30 mg, and 36 mg tablets. KYMBEE is also available as a 22.75 mg/mL oral suspension.This safety information is not comprehensive. For more information, please
More news about: Upsher-Smith Laboratories, LLC
Jun 23, 2026, 10:00 ET BLOCK STRONG LAUNCHES NEW SUMMER CAMPAIGN "IF THESE WALLS COULD TALK"
https://youtu.be/AtiIJM3J4mg.The campaign's television and digital spot follows a family throughout different stages of life inside a concrete block home.
More news about: Block Strong
Jun 23, 2026, 08:56 ET MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
results to new patients. There could be significant differences. ∞ Reached using optimal settings, Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time. SmartGuard™ feature settings for each single patient must be defined
More news about: MiniMed
Jun 23, 2026, 08:43 ET FRISS Joins AF Corse USA as Official Partner for 2026 Racing Season
lapse in concentration at the wrong moment, performance is often determined by the ability to stay present when it matters most. Available in 75mg and 100mg strengths, FRISS delivers a measured source of caffeine designed to help users maintain control of their energy throughout the day, without the
More news about: FRISS
Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
plaque psoriasis1Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg1Nearly a third of people living
More news about: AbbVie
Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
plaque psoriasis1Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg1Nearly a third of people living
More news about: AbbVie
Jun 23, 2026, 00:01 ET Signify Enhances Philips Hue Matter Support Through Collaboration with Silicon Labs
MG26 and
More news about: Silicon Labs
Jun 22, 2026, 14:14 ET Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the efficacy signal at the 2 mg/kg dose level and initial safety and tolerability data at the 3 mg/kg dose level.Completion of the PDAC enrollment represents a significant milestone for the TWINPEAK study,
More news about: Phanes Therapeutics, Inc.
Jun 22, 2026, 11:49 ET Ryde: Tackles SLEEP, Launching Its Newest Wellbeing Functional Shot In Partnership With Rob Gronkowski
for individuals under the age of 18 or those sensitive to caffeine or melatonin. Ryde: Energize includes 200mg of caffeine, Ryde: Focus includes 150mg of caffeine, and Ryde: Sleep includes 5mg of melatonin. Please check label before consumption to see if Ryde is right for you. Ryde: Energy, Focus and
More news about: Ryde:
Jun 22, 2026, 09:06 ET 蘆康沙妥珠單抗聯合奧希替尼一線治療EGFR突變NSCLC轉化研究成果刊發於《Cancer Cell》
果與臨床開發計劃，公司正在推進一項III期注冊研究（試驗編號：NCT06670196），將sac-TMT聯合奧希替尼與奧希替尼單藥一線治療局部晚期或轉移性EGFR突變非鱗狀NSCLC進行對比。該研究旨在評估sac-TMT（4 mg/kg，每兩周給藥一次）聯合奧希替尼相較於奧希替尼單藥在此適應症下的療效與安全性。該研究已在中國完成全部受試者入組，目前進入隨訪與數據成熟階段。除此之外，公司還在推進sac-TMT用於更早期EGFR突變NSCLC的臨床探索。一項II期臨床研究（試驗編號：NCT07329322）正在開展，評估sac-TMT聯合奧希替尼或sac-TMT單藥用於可切除EGFR突變NSCLC新輔助治療，進一步挖掘sac-TMT在圍手術期治療中的潛在價值。本次研究成果刊發於《Cancer
More news about: 科倫博泰